Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesBMT/SCT after conditioning for haematological cancersRR 0.89 [0.80, 0.99]6 studies · 852 participantsLow
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesRT to head and neck with cisplatin/fluorouracilRR 0.91 [0.83, 1.00]3 studies · 471 participantsModerate
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesChemotherapy alone for mixed cancersRR 0.56 [0.45, 0.70]4 studies · 344 participantsModerate